Topics:

Infectious Disease Emergencies: Part 1, Fever and Rash

Infectious Disease Emergencies: Part 1, Fever and Rash

ABSTRACT: Early recognition of potentially life-threatening infections, such as Rocky Mountain spotted fever (RMSF), meningococcemia, and necrotizing fasciitis, is vital to ensure timely treatment. The characteristic rash of RMSF begins on the ankles and wrists and spreads both centrally and to the palms and soles; it often starts as a macular or maculopapular eruption and then becomes petechial. The diagnosis is largely clinical, especially in the early stages of the disease, when there is no reliable diagnostic test. Meningococcemia typically starts with a prodrome of cough, headache, and pharyngitis, which is followed by rapid onset of fever, chills, arthralgias, and myalgias. Patients appear ill, and most have a rash. Key features that help distinguish necrotizing fasciitis from simple cellulitis are poorly defined margins of affected tissue that spread rapidly, with darkening of erythema to a reddish-purple color; rapidly worsening pain that is out of proportion to the physical findings; and crepitations over the affected area.

 

Whether in a primary care office or an emergency department, it is imperative for any front-line clinician to be able to quickly recognize potentially life-threatening infections. The purpose of this 3-part series is to highlight infectious diseases that are associated with high morbidity and mortality and/or difficulty in diagnosis.

We will provide a practical approach to the triage, diagnosis, and treatment of these diseases, specifically in adults.

In this article, we discuss serious illnesses that present with rash and fever: Rocky Mountain spotted fever (RMSF), meningococcemia, and necrotizing fasciitis (Table). In coming issues, we will address staphylococcal and streptococcal toxic shock syndromes and CNS infections.

ROCKY MOUNTAIN SPOTTED FEVER

Epidemiology. Rickettsia rickettsii, a gram-negative, obligate intracellular bacterium, is the pathogen responsible for RMSF. This potentially lethal tick-borne disease is the most common rickettsial infection in the United States. About 250 to 1200 cases of RMSF have been reported annually over the past 50 years, and many more cases probably go unreported.1 In 2004, 1454 cases were reported, which was a considerable increase from 947 in the previous year.2

Although more prevalent in the southeastern and south central states, RMSF is found across the United States in rural, suburban, and even urban areas. The ease and frequency of interstate travel have probably contributed to its spread.3 Most infections occur during the spring and summer, when frequent human outdoor activity coincides with an increased number of adult and nymphal ticks; however, rare cases of RMSF have been documented in the winter.

The disease is transmitted by the bite of Dermacentor variabilis, the American dog tick; Dermacentor andersoni, the Rocky Mountain wood tick; and Rhipicephalus sanguineus, the common brown dog tick. Up to one-third of patients with confirmed RMSF do not recall a recent tick bite or tick contact; rarely, the disease can be transmitted from infective tick tissues or feces by conjunctival contamination, transcutaneous transmission, or inhalation.4,5

Clinical features. Symptoms appear from 2 to 14 days after exposure, with most occurring between 5 and 7 days. A rash usually develops between the third and fifth days of illness6,7; however, the rash can be delayed and may not be present when a patient first seeks medical attention,8,9 or it may even be completely absent in up to 10% of cases. Such cases of "spotless" RMSF may be severe and even fatal.10 Special care is needed, especially in dark-skinned persons, because the rash may be easily overlooked. The rash begins on the ankles and wrists and spreads both centrally and to the palms and soles; it often starts as a macular or maculopapular eruption and then usually becomes petechial (Figure 1). Other early nonspecific symptoms may include7:

Figure 1 – This rash started on a 55-year-old man's forearms and legs and spread to his trunk (A), palms (B), and soles. He also had fever, headache, myalgia, arthralgia, and a history of a recent tick bite. Rocky Mountain spotted fever was diagnosed.

• Fever (in virtually all cases).

• Severe headache.

• Malaise.

• Myalgias.

• Arthralgias.

• Nausea with or without vomiting.

• Abdominal pain.

Additional manifestations are cough, bleeding, edema, confusion, focal neurological signs, and seizures.

Diagnosis. The diagnosis of RMSF is largely clinical, especially in the early stages of the disease, when there is no reliable diagnostic test.9 Later in the course of the illness, the diagnosis can be made by skin biopsy or serology (usually with an indirect fluorescent antibody test, but enzyme immunoassay and complement fixation and latex agglutination, indirect hemagglutination, and microagglutination assays are also useful).11 Rickettsial blood culture, the most sensitive and specific test, is not readily available; it is limited primarily to research centers. Other laboratory studies (eg, complete blood cell count, comprehensive metabolic panel, and lumbar puncture) may have nonspecific aberrant results.

Treatment. Timely treatment is crucial. Because of the difficulty in making a definitive diagnosis of RMSF in the early stages of the disease, initiation of empiric therapy is based largely on clinical judgment and epidemiological setting. Antibiotic therapy consists of doxycycline, 100 mg twice a day (chloramphenicol, 50 mg/kg per day in 4 divided doses, is the alternative treatment for pregnant women); typically, a 5- to 7day course is sufficient. Treatment should extend at least 3 days after a patient becomes afebrile. Hospitalization is usually unnecessary; however, the patient's overall clinical picture is ultimately the determining factor.

MENINGOCOCCEMIA

Etiology. The causative agent for meningococcemia is Neisseria meningitides.

It is transmitted by aerosols or secretions from the nasopharynx. Infection with this encapsulated gram-negative diplococcus can result in asymptomatic pharyngeal colonization or invasive disease, manifested by 1 of 3 syndromes12:

• Meningitis.

• Meningitis with accompanying meningococcemia.

• Meningococcemia without clinical evidence of meningitis.

Epidemiology. In the United States, the incidence of meningococcal disease is estimated to be 0.3 to 1.0 cases per 100,000 population. About 10% to 14% of cases are fatal (most deaths occur within 48 hours), and 11% to 19% of those who survive have permanent hearing loss, mental retardation, loss of limbs, or other serious sequelae.

Clinical features. Because of the rapid progression of meningococcal infection, early recognition is vital. Initially, a nonspecific prodrome of cough, headache, and pharyngitis may be present, which is then followed by rapid onset of fever (initially moderate, but high with fulminant disease), chills, arthralgias, and myalgias.

Patients appear ill and often present with a petechial or purpuric rash (50% to 80% of cases),12,13 that involves the axillae, flanks, wrists, and ankles (Figure 2).

Figure 2 – This petechial rash occurred in a 23-year-old man with a 2-day history of fever and chills. Culture confirmed the diagnosis of meningococcal meningitis. (Photograph courtesy of Charles S. Bryan, MD.)

Tachycardia and mild hypotension may also be evident, but patients will rapidly decompensate, becoming hemodynamically unstable, and may eventually show signs of end-organ damage. Headache, neck stiffness, lethargy, and drowsiness are common symptoms if meningitis is present with or without meningococcemia; patients with meningitis may also have decreased mentation that can progress to coma. Meningococcal infection can also manifest as either pericarditis (potentially leading to tamponade) or arthritis.

Diagnosis and treatment. Culture of meningococci from blood, spinal fluid, joint fluid or, occasionally, skin lesions establishes a definitive diagnosis. However, treatment should not be delayed while awaiting culture results. When meningococcal infection is suspected, prompt initiation of antibiotic therapy and supportive measures for vascular collapse (if present) is of the utmost importance. Hospitalization is almost always required.

Penicillin, chloramphenicol (for patients with penicillin allergy), and third-generation cephalosporins are all effective in the treatment of meningococcemia. Unfortunately, meningococcal resistance to both penicillin and chloramphenicol has been demonstrated14-16; as a result, third-generation cephalosporins (eg, cefotaxime, ceftriaxone, ceftizoxime, and ceftazidime) are preferable, especially because these antibiotics have superior cerebrospinal fluid penetration. Remember that there is likely to be only 2% cross-reactivity between penicillins and cephalosporins produced after 1980 (when cephalosporins no longer were contaminated with penicillin), based on those patients who showed actual penicillin sensitivity with positive skin tests.

Meningococcemia remains a virulent disease: mortality rates have essentially not changed during the past 30 years, despite advances in treatment and supportive care. Thus, the importance of early recognition cannot be overemphasized, since early treatment may help prevent or halt the progression of the infection and potentially help forestall sequelae.

NECROTIZING FASCIITIS

Clinical features. The hallmark of necrotizing fasciitis is preservation of the skin itself, while progressive destruction of fascia and fat occurs.17 Various bacterial pathogens are responsible for this deep-seated infection of the subcutaneous tissue, which can be categorized as 3 clinical types:

• Type I necrotizing fasciitis: a polymicrobial infection caused by aerobic and anaerobic bacteria that is most commonly seen in the postoperative period and in persons with diabetes or peripheral vascular disease.18

• Type II necrotizing fasciitis: a monomicrobial infection that involves either group A streptococcus (ie, Streptococcus pyogenes) or community-associated methicillin-resistant

Staphylococcus aureus (MRSA).19

•Type III necrotizing fasciitis: also known as clostridial myonecrosis (involvement

of Clostridium species) or gas gangrene and typically associated with recent trauma or surgery.

Necrotizing fasciitis is a potentially malignant disease process, and early recognition is critical because it can rapidly progress from a presumed minor infection to extensive tissue destruction, sepsis, loss of limb, or death.20

Physical findings may be nonspecific, and initially patients may present with only cellulitic or erythematous skin changes. Key features that help distinguish necrotizing fascitis from simple cellulitis are:

• Poorly defined margins of affected tissue that spread rapidly, with darkening of erythema to a reddish purple color (Figure 3).

• Pain that is out of proportion to the degree of apparent cellulitis and that increases rapidly over time.

• Crepitance over the affected area (present in about 10% of cases18).

Figure 3 – Necrotizing fasciitis, seen here in an elderly woman with type 2 diabetes mellitus, is characterized by poorly defined margins of affected tissue that spread rapidly, with darkening of erythema to a reddish purple color. (Photograph courtesy of Noah S. Scheinfeld, MD, JD.)

In addition, blisters or bullae may form; they are initially filled with clear fluid, but they can rapidly change to a blue or maroon appearance. This finding represents extensive deep soft tissue destruction. At this stage of the disease, patients usually exhibit fever and other signs of systemic toxicity.

Diagnosis. Laboratory findings are nonspecific; they typically reflect leukocytosis with left shift, and elevations in serum lactate, creatine kinase, creatinine, and C-reactive protein concentrations.21,22 Imaging studies (ie, soft tissue radiographs, CT scans, and MRI scans) are also of limited value in the diagnosis of necrotizing fascitis; they are only helpful in detecting the presence of gas within the affected tissue. At best, CT may be of use when the diagnosis of necrotizing fasciitis is considered clinically unlikely and deep tissue involvement needs to be ruled out. MRI may only confound matters because it can be overly sensitive and thereby overestimate deep tissue involvement, or it may be unable to distinguish necrotizing fasciitis from cellulitis or inflammation.23 The diagnosis of necrotizing fasciitis is based on clinical suspicion, and prompt intervention should not be delayed while awaiting the results of imaging studies.

Treatment. Although antibiotic therapy and hemodynamic support are vital, definitive treatment is timely surgical debridement of necrotic tissue. Patients must be promptly hospitalized, and empiric, broad-spectrum antibiotic therapy should be started to ensure coverage of anaerobic/aerobic bacteria, as well as group A streptococcus and MRSA. A typical regimen consists of piperacillin/tazobactam, clindamycin, and vancomycin. Despite optimal therapy, however, mortality associated with necrotizing fasciitis is as high as 40%.

References

REFERENCES:

1. Centers for Disease Control and Prevention. Rocky mountain spotted fever. March 2008. http://www.cdc.gov/ncidod/dvrd/rmsf/index.htm. Accessed July 1, 2009.

2. Centers for Disease Control and Prevention. Summary of provisional cases of selected notifiable disease, United States, cumulative, week ending December 18, 2004 (50th week). MMWR. 2004;53: 1185-1193.

3. Salgo MP, Telzak EE, Currie B, et al. A focus of Rocky Mountain spotted fever within New York City. N Engl J Med. 1988;318:1345-1348.

4. Treadwell TA, Holman RC, Clarke MJ, et al. Rocky Mountain spotted fever in the United States, 1993-1996. Am J Trop Med Hyg. 2000;63:21-26.

5. Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg. 1995;52:405-413.

6. Centers for Disease Control and Prevention. Fatal cases of Rocky Mountain spotted fever in family clusters—three states, 2003. MMWR. 2004;53: 407-410.

7. Kirk JL, Sexton DJ, Fine DP, Muchmore HG. Rocky Mountain spotted fever. A clinical review based on 48 confirmed cases. Medicine (Baltimore). 1990;69:35-45.

8. Helmick CG, Bernard KW, D'Angelo LJ. Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis 1984;150:480-488.

9. Kirkland KB, Wilkinson WE, Sexton DJ. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis. 1995;20:1118-1121.

10. Sexton DJ, Corey GR. Rocky Mountain "spotless" and "almost spotless" fever: a wolf in sheeps' clothing. Clin Infect Dis. 1992;15:439-448.

11. Walker DH, Burday MS, Folds JD. Laboratory diagnosis of Rocky Mountain spotted fever. South Med J. 1980;73:1443-1446.

12. Wolf RE, Birbara CA. Meningococcal infections at an army training center. Am J Med. 1968;44:243255.

13. Carpenter RR, Petersdorf RG. The clinical spectrum of bacterial meningitis. Am J Med. 1962; 33:262-275.

14. Sprott MS, Kearns AM, Field JM. Penicillin insensitive Neisseria meningitis. Lancet. 1988;1: 1167-1170.

15. Mendelman PM, Campos J, Chaffin DO, et al. Relative penicillin G resistance in Neisseria meningitidis and reduced affinity of penicillin binding protein 3. Antimicrob Agents Chemother. 1988;32:706-710.

16. Galimand M, Gerbaud G, Guibourdenche M, et al. High-level chloramphenicol resistance in Neisseria meningitidis [published correction appears in N Engl J Med. 1999;340:824]. N Engl J Med. 1998; 339:868-874.

17. Gozal D, Ziser A, Shupak A, et al. Necrotizing fasciitis. Arch Surg. 1986;121:233-239.

18. Wong CH, Chang HC, Pasupathy S, et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003;85-A:1454-1460.

19. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352:1445-1453.

20. Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet. 1994;344:1111-1115.

21. Simonart T, Simonart JM, Derdelinckx I, et al. Value of standard laboratory tests for the early recognition of group A beta-hemolytic streptococcal necrotizing fasciitis. Clin Infect Dis. 2001;32:E9-E12.

22. Yaghoubian A, de Virgilio C, Dauphine C, et al. Use of admission serum lactate and sodium levels to predict mortality in necrotizing soft-tissue infections. Arch Surg. 2007;142:840-846.

23. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR. 1998;170:615-620.

 
Loading comments...
Please Wait 20 seconds or click here to close